Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941288 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT03941288: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03941288 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03941288, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Researchers are looking at the effects of a cannabidiol medication on stomach function in people with gastroparesis (a paralyzed stomach) and people with dyspepsia (an upset stomach caused by improper functioning of the stomach's muscles or nerves).
Interventions
- DRUG Cannabidiol
- OTHER placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941288
The ClinicalTrials.gov registry entry for NCT03941288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cannabidiol is the first listed.
NCT03941288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03941288 about?
NCT03941288 is a clinical study titled "Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia". Researchers are looking at the effects of a cannabidiol medication on stomach function in people with gastroparesis (a paralyzed stomach) and people with dyspepsia (an upset stomach caused by improper functioning of the stomach's muscles or nerves).
What is the current status of trial NCT03941288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2019-09-04. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT03941288?
The interventions under investigation include: Cannabidiol (DRUG), placebo (OTHER).
Who is sponsoring clinical trial NCT03941288?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.